[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100234656":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":42,"centralContacts":46,"locations":53,"responsibleParty":267,"collaborators":51,"id":269,"slug":270,"hasResults":271,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":51,"eligibilityCriteria":275,"healthyVolunteers":271,"sex":276,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":51,"studyType":282,"phases":283,"briefSummary":286,"conditions":287,"keywords":292,"overallStatus":56,"whyStopped":51,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":308},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Melanoma","EXPERIMENTAL","Participants aged 6 months to \\\u003C18 years with melanoma receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to \\\u003C12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma closed with Amendment 13.",[13],"Biological: Pembrolizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Solid Tumors and Other Lymphomas","Participants aged 6 months to \\\u003C18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Relapsed Refractory Classical Hodgkin Lymphoma (rrcHL)","Participants aged 3 years to \\\u003C18 years with rrcHL receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), IV Q3W. Enrollment of participants with rrcHL was closed with Amendment 13.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Microsatellite Instability-High (MSI-H)","Participants aged 6 months to \\\u003C18 years with MSI-H solid tumors receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), IV Q3W. Enrollment of participants with MSI-H solid tumors was closed with Amendment 13.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Tumor Mutational Burden-High (TMB-H)","Participants aged 6 months to \\\u003C18 years with TMB-H ≥10 mutation\u002FMb solid tumors receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), IV Q3W. Enrollment of participants with TMB-H solid tumors was closed with Amendment 13.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Adjuvant Melanoma","Participants aged 12 years to \\\u003C18 years with resected high-risk Stage IIB, IIC, III, or IV melanoma receive pembrolizumab, starting dose 2 mg\u002Fkg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W).",[13],[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"BIOLOGICAL","Pembrolizumab","IV infusion",[31,9,23,19,15,27],[41],"MK-3475",[43],{"name":44,"affiliation":5,"role":45},"Medical Director","STUDY_DIRECTOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[54,68,78,88,97,107,117,127,141,155,169,183,197,211,225,239,253],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":51},"Call for Information (Investigational Site 0019)","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-104.83192,39.72943,{"lat":66,"lon":65},{"facility":69,"status":56,"city":70,"state":71,"zip":72,"country":60,"countryCode":61,"cosmosGeoPoint":73,"geoPoint":77,"contacts":51},"Call for Information (Investigational Site 0024)","Chicago","Illinois","60637",{"type":63,"coordinates":74},[75,76],-87.65005,41.85003,{"lat":76,"lon":75},{"facility":79,"status":56,"city":80,"state":81,"zip":82,"country":60,"countryCode":61,"cosmosGeoPoint":83,"geoPoint":87,"contacts":51},"Call for Information (Investigational Site 0026)","Boston","Massachusetts","02445",{"type":63,"coordinates":84},[85,86],-71.05977,42.35843,{"lat":86,"lon":85},{"facility":89,"status":56,"city":90,"state":90,"zip":91,"country":60,"countryCode":61,"cosmosGeoPoint":92,"geoPoint":96,"contacts":51},"Call for Information (Investigational Site 0031)","New York","10032",{"type":63,"coordinates":93},[94,95],-74.00597,40.71427,{"lat":95,"lon":94},{"facility":98,"status":56,"city":99,"state":100,"zip":101,"country":60,"countryCode":61,"cosmosGeoPoint":102,"geoPoint":106,"contacts":51},"Call for Information (Investigational Site 0070)","Fargo","North Dakota","58102",{"type":63,"coordinates":103},[104,105],-96.7898,46.87719,{"lat":105,"lon":104},{"facility":108,"status":56,"city":109,"state":110,"zip":111,"country":60,"countryCode":61,"cosmosGeoPoint":112,"geoPoint":116,"contacts":51},"Call for Information (Investigational Site 0071)","Sioux Falls","South Dakota","57117",{"type":63,"coordinates":113},[114,115],-96.72796,43.54369,{"lat":115,"lon":114},{"facility":118,"status":56,"city":119,"state":120,"zip":121,"country":60,"countryCode":61,"cosmosGeoPoint":122,"geoPoint":126,"contacts":51},"Call for Information (Investigational Site 0054)","Dallas","Texas","75235",{"type":63,"coordinates":123},[124,125],-96.80667,32.78306,{"lat":125,"lon":124},{"facility":128,"status":56,"city":129,"state":51,"zip":51,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"MSD Brasil","São Paulo","Brazil","BR",{"type":63,"coordinates":133},[134,135],-46.63611,-23.5475,{"lat":135,"lon":134},[138],{"name":139,"role":49,"phone":140,"phoneExt":51,"email":51},"MSD Online","0800 012 22 32",{"facility":142,"status":56,"city":143,"state":51,"zip":51,"country":144,"countryCode":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"MSD France","Paris","France","FR",{"type":63,"coordinates":147},[148,149],2.3488,48.85341,{"lat":149,"lon":148},[152],{"name":153,"role":49,"phone":154,"phoneExt":51,"email":51},"Dominique Blazy","33 147548990",{"facility":156,"status":56,"city":157,"state":51,"zip":51,"country":158,"countryCode":159,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"MSD Sharp & Dohme GmbH","München","Germany","DE",{"type":63,"coordinates":161},[162,163],13.31243,51.60698,{"lat":163,"lon":162},[166],{"name":167,"role":49,"phone":168,"phoneExt":51,"email":51},"German Medical Information Center","49 800 673 673 673",{"facility":170,"status":56,"city":171,"state":51,"zip":51,"country":172,"countryCode":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Merck Sharp & Dohme Co. Ltd.","Hod HaSharon","Israel","IL",{"type":63,"coordinates":175},[176,177],34.8932,32.15934,{"lat":177,"lon":176},[180],{"name":181,"role":49,"phone":182,"phoneExt":51,"email":51},"Gally Teper","972-9-9533310",{"facility":184,"status":56,"city":185,"state":51,"zip":51,"country":186,"countryCode":187,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"MSD Italia S.r.l.","Rome","Italy","IT",{"type":63,"coordinates":189},[190,191],12.51133,41.89193,{"lat":191,"lon":190},[194],{"name":195,"role":49,"phone":196,"phoneExt":51,"email":51},"Barbara Capaccetti","39 06361911",{"facility":198,"status":56,"city":199,"state":51,"zip":51,"country":200,"countryCode":201,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Merck Sharp & Dohme BV","Haarlem","Netherlands","NL",{"type":63,"coordinates":203},[204,205],4.63683,52.38084,{"lat":205,"lon":204},[208],{"name":209,"role":49,"phone":210,"phoneExt":51,"email":51},"Caroline Doornebos","31 23 515 3362",{"facility":212,"status":56,"city":213,"state":51,"zip":51,"country":214,"countryCode":215,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Merck Sharp & Dohme Lda.","Paço de Arcos","Portugal","PT",{"type":63,"coordinates":217},[218,219],-9.29143,38.69569,{"lat":219,"lon":218},[222],{"name":223,"role":49,"phone":224,"phoneExt":51,"email":51},"Paula Martins de Jesus","00351-214465803",{"facility":226,"status":56,"city":227,"state":51,"zip":228,"country":229,"countryCode":51,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"MSD Korea LTD","Seoul","4130","South Korea",{"type":63,"coordinates":231},[232,233],126.9784,37.566,{"lat":233,"lon":232},[236],{"name":237,"role":49,"phone":238,"phoneExt":51,"email":51},"Jongho Ahn","82-2-331-2000 2015",{"facility":240,"status":56,"city":241,"state":51,"zip":51,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"MSD Sweden","Stockholm","Sweden","SE",{"type":63,"coordinates":245},[246,247],18.06871,59.32938,{"lat":247,"lon":246},[250],{"name":251,"role":49,"phone":252,"phoneExt":51,"email":51},"Tryggve Ljung","46 (0)70 545 28 66",{"facility":254,"status":56,"city":255,"state":51,"zip":51,"country":256,"countryCode":257,"cosmosGeoPoint":258,"geoPoint":262,"contacts":263},"Merck Sharp & Dohme Ltd.","London","United Kingdom","UK",{"type":63,"coordinates":259},[260,261],-0.12574,51.50853,{"lat":261,"lon":260},[264],{"name":265,"role":49,"phone":266,"phoneExt":51,"email":51},"Natalie White","44 (0) 208 154 8000",{"type":268,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100234656","phase-1-a-study-of-pembrolizumab-mk-3475-in-pediatric-participants-with-an-advanced-solid-tumor-or-lymphoma-mk-3475-051keynote-051-100234656",false,"NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)","A Phase I\u002FII Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)","Inclusion Criteria:\n\n* Between 6 months and \\\u003C18 years of age on day of signing informed consent is documented.\n* Histologically- or cytologically-documented, locally-advanced, or metastatic solid malignancy or lymphoma that is incurable and has failed prior standard therapy, or for which no standard therapy exists, or for which no standard therapy is considered appropriate\n* Any number of prior treatment regimens\n* Tissue (or lymph node biopsy for rrcHL participants) available from an archival tissue sample or, if appropriate, a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated\n* Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma\n* Measurable disease based on RECIST 1.1 (Or based on IWG \\[Cheson, 2007\\] \\[i.e., measurement must be \\>15 mm in longest diameter or \\>10 mm in short axis\\] for rrcHL participants)\n* Participants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolled\n* Lansky Play Scale ≥50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ≥50 for participants \\>16 years of age\n* Adequate organ function\n* Female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours before the first dose of study medication\n* Female participant is not a woman of childbearing potential (WOCBP) or is a WOCBP who is abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of study intervention\n* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Demonstrate adequate organ function.\n\nExclusion Criteria:\n\n* Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation\u002Frandomization\n* Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the date of allocation\u002Frandomization\n* Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent\n* Prior radiotherapy within 2 weeks of start of study treatment\n* Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical carcinoma in situ) with potentially curative therapy, or in situ cervical cancer\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Tumor(s) involving the brain stem\n* Severe hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* Active infection requiring systemic therapy\n* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication\n* Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 \\[CTLA-4\\], OX-40, CD137)\n* Human immunodeficiency virus (HIV)\n* Hepatitis B or C\n* Known history of active tuberculosis (TB; Bacillus tuberculosis)\n* Received a live vaccine within 30 days of planned start of study medication\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had an allogeneic hematopoietic transplant \\>5 years ago are eligible as long as there are no symptoms of Graft Versus Host Disease \\[GVHD\\].)\n* History or current evidence of any condition, therapy, or laboratory abnormality, or known severe hypersensitivity to any component or analog of the trial treatment, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study\n* Known psychiatric or substance abuse disorders that would interfere with the requirements of the study","ALL","6 Months","17 Years",{"count":280,"type":281},370,"ESTIMATED","INTERVENTIONAL",[284,285],"PHASE1","PHASE2","Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these:\n\n* Advanced, which means cancer spread in the body or cannot be removed with surgery\n* Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared)\n* Refractory, which means cancer did not respond to previous treatment\n\nPembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away.\n\nWith Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed.\n\nWith Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \\\u003C18 years old with advanced melanoma.",[9,288,289,290,291],"Lymphoma","Solid Tumor","Classical Hodgkin Lymphoma","Microsatellite-instability-high Solid Tumor",[293,294,295,296,297,298],"PD1","PD-1","PDL1","PD-L1","cHL","MSI-H","2026-05-28",{"date":301,"type":302},"2026-06-01","ACTUAL",{"date":304,"type":302},"2015-03-19",{"date":306,"type":281},"2028-02-02",{"name":5,"class":6},17]